Most Read Articles
6 days ago
The choice between nonvitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) for stroke prevention appears to be complex and largely heterogenous across different, countries, a new study has found.
Yesterday
Monotherapy with tenofovir disoproxil fumarate increases virologic response for up to 240 weeks in pretreated patients with hepatitis B virus infection (HBV) who are resistant to entecavir and/or adefovir, a new study has found.
Elvira Manzano, 2 days ago
Long-term treatment with the interleukin-5 receptor alpha-directed cytolytic monoclonal antibody benralizumab led to long-term control of asthma, improvement in pulmonary function, and was safe in patients with severe eosinophilic asthma in the 2-year integrated analysis of the SIROCCO, CALIMA, and ZONDA pivotal studies plus the BORA extension study reported at ATS 2019.
Pearl Toh, 2 days ago
Emerging evidence is showing that the two major new classes of antidiabetic drugs — SGLT2* inhibitors and GLP-1** receptor agonists (RAs) — not only confer cardiovascular (CV) benefits to patients with type 2 diabetes (T2D), they also delay the loss of kidney function among these patients, potentially providing nephrologists with an additional tool in their armamentarium for managing patients with chronic kidney disease (CKD) in the future.

Computerized cognitive training improves cognitive function, brain connectivity

19 May 2019

A computerized cognitive training regimen effectively improves global cognition and brain plasticity in patients with vascular cognitive impairment, a recent study has found.

Sixty patients were randomly assigned to receive either the cognitive training regimen (n=30; mean age, 63.9±7.9 years; 40.0 percent female) or to an active control group (n=30; mean age, 64.9±6.6 years; 26.7 percent female). Those assigned to the training underwent a computerized, multidomain and adaptive programme, which lasted for 7 weeks. Domains included problem solving, executive control, calculation, long-term and working memory, processing speed, perception, attention, reasoning, and calculation.

After 7 weeks, there was a significant improvement in Montreal Cognitive Assessment (MoCA) scores in patients who received cognitive training (change from baseline, 3.356; 95 percent CI, 1.467–5.244). No such effect was observed in the active control group (change from baseline, –0.085; –2.062 to 1.892; effect size, 0.637; 0.115–1.153).

This difference did not persist until the 6-month follow-up (training group: change from baseline, 2.224; 0.256–4.192; active control: change from baseline, 1.358; –0.899 to 3.614; effect size, 0.866; –0.361 to 0.653).

Notably, from baseline to the end of the study, researchers also observed a significant increase in the connectivity between the left dorsolateral prefrontal cortex and median prefrontal cortex. This was true for participants who received the cognitive training but not in those who were assigned to the active control.

The improvement in connectivity was likewise significantly and positively associated with changes in MoCA in the training (r, 0.463; p=0.017) but not in the active control (r, 0.08; p=0.68) group.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
6 days ago
The choice between nonvitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) for stroke prevention appears to be complex and largely heterogenous across different, countries, a new study has found.
Yesterday
Monotherapy with tenofovir disoproxil fumarate increases virologic response for up to 240 weeks in pretreated patients with hepatitis B virus infection (HBV) who are resistant to entecavir and/or adefovir, a new study has found.
Elvira Manzano, 2 days ago
Long-term treatment with the interleukin-5 receptor alpha-directed cytolytic monoclonal antibody benralizumab led to long-term control of asthma, improvement in pulmonary function, and was safe in patients with severe eosinophilic asthma in the 2-year integrated analysis of the SIROCCO, CALIMA, and ZONDA pivotal studies plus the BORA extension study reported at ATS 2019.
Pearl Toh, 2 days ago
Emerging evidence is showing that the two major new classes of antidiabetic drugs — SGLT2* inhibitors and GLP-1** receptor agonists (RAs) — not only confer cardiovascular (CV) benefits to patients with type 2 diabetes (T2D), they also delay the loss of kidney function among these patients, potentially providing nephrologists with an additional tool in their armamentarium for managing patients with chronic kidney disease (CKD) in the future.